163 related articles for article (PubMed ID: 26055178)
1. Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Chen JH; Yu HJ; Hsu C; Mehta RS; Carpenter PM; Su MY
Transl Oncol; 2015 Jun; 8(3):204-9. PubMed ID: 26055178
[TBL] [Abstract][Full Text] [Related]
2. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
Chen JH; Yu H; Lin M; Mehta RS; Su MY
Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
[TBL] [Abstract][Full Text] [Related]
3. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Petta F; Serra T; Masiello V; Scrofani AR; Barone R; Orlandi A; Valentini V; Manfredi R
Diagn Interv Imaging; 2020 Oct; 101(10):649-655. PubMed ID: 32654985
[TBL] [Abstract][Full Text] [Related]
4. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
5. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: Association with pathologic complete response.
Dong JM; Wang HX; Zhong XF; Xu K; Bian J; Feng Y; Chen L; Zhang L; Wang X; Ma DJ; Wang B
Medicine (Baltimore); 2018 Oct; 97(43):e12965. PubMed ID: 30412117
[TBL] [Abstract][Full Text] [Related]
6. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.
Oh SJ; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
Br J Radiol; 2018 Jul; 91(1088):20170550. PubMed ID: 29848015
[TBL] [Abstract][Full Text] [Related]
7. Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.
You C; Peng W; Zhi W; He M; Liu G; Xie L; Jiang L; Hu X; Shen X; Gu Y
Transl Oncol; 2017 Oct; 10(5):786-792. PubMed ID: 28806712
[TBL] [Abstract][Full Text] [Related]
8. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
[TBL] [Abstract][Full Text] [Related]
9. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
Arasu VA; Kim P; Li W; Strand F; McHargue C; Harnish R; Newitt DC; Jones EF; Glymour MM; Kornak J; Esserman LJ; Hylton NM;
J Breast Imaging; 2020 Aug; 2(4):352-360. PubMed ID: 32803155
[TBL] [Abstract][Full Text] [Related]
11. Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI.
La Forgia D; Vestito A; Lasciarrea M; Comes MC; Diotaiuti S; Giotta F; Latorre A; Lorusso V; Massafra R; Palmiotti G; Rinaldi L; Signorile R; Gatta G; Fanizzi A
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33915842
[TBL] [Abstract][Full Text] [Related]
12. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
13. Background parenchymal enhancement on breast MRI and mammographic breast density: correlation with tumour characteristics.
Kim MY; Choi N; Yang JH; Yoo YB; Park KS
Clin Radiol; 2015 Jul; 70(7):706-10. PubMed ID: 25824280
[TBL] [Abstract][Full Text] [Related]
14. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
15. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
[TBL] [Abstract][Full Text] [Related]
16. Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer.
Öztürk M; Polat AV; Süllü Y; Tomak L; Polat AK
J Breast Health; 2017 Jan; 13(1):27-33. PubMed ID: 28331765
[TBL] [Abstract][Full Text] [Related]
17. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
[TBL] [Abstract][Full Text] [Related]
19. Background parenchymal enhancement: behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response.
Teixeira SRC; de Camargo Júnior HSA; Cabello C
Radiol Bras; 2020; 53(2):95-104. PubMed ID: 32336824
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
Nguyen AA; Arasu VA; Strand F; Li W; Onishi N; Gibbs J; Jones EF; Joe BN; Esserman LJ; Newitt DC; Hylton NM
Tomography; 2020 Jun; 6(2):101-110. PubMed ID: 32548286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
